LASONIL ANTI-PAIN * GEL 50G 10%
Local treatment of bruises, sprains, myalgia, muscle tears, stiff neck.
Dosage and method of use
2-4 applications per day on the painful area. Elderly patients should adhere to the minimum dosages indicated above. Apply a thin layer of gel on the area to be treated with a light massage. Use the medicine for the shortest period possible. Wash your hands thoroughly and for a long time after application.
- Hypersensitivity to the active substance or to any of the excipients. Due to the possibility of cross-sensitization, the medicinal product should not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding - Children and adolescents under 14 years of age.
Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. A few cases of bullous eruptions of varying severity have also been reported, including Stevens Johnson syndrome, and toxic epidermal necrolysis (very rarely). Photosensitivity reactions are possible. Reporting of suspected adverse reactions The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of the Italian Medicines Agency. Website: http://www.agenziafarmaco.gov.it/it/responsabili.
It is advisable to avoid the application of LASONIL ANTIDOLORE on open wounds or skin lesions. The use of LASONIL ANTIDOLORE, as with any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of LASONIL ANTIDOLORE should be discontinued in women who have fertility problems or who are undergoing fertility investigations. The use of LASONIL ANTIDOLORE, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt the treatment and adopt appropriate therapeutic measures. To avoid more serious phenomena of hypersensitivity or photosensitization, the patient must not expose himself to direct sunlight, including the solarium, during the treatment and in the following two weeks. In case of allergic reactions or major adverse reactions (skin reactions, some of them fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) therapy must be discontinued immediately (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of skin reactions occur in most cases within the first month of treatment. Do not use LASONIL ANTIDOLORE together with another NSAID or, in any case, do not use more than one NSAID at a time. Important information about some of the ingredients of LASONIL ANTIDOLORE: The medicine contains methyl sodium para-hydroxybenzoate and ethyl sodium para-hydroxybenzoate which can cause allergic reactions (including delayed).
Pregnancy and breastfeeding
The use of LASONIL ANTIDOLORE is contraindicated in pregnancy and breastfeeding. Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased by less than 1% up to about 1.5%. The risk was considered to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo / fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals given prostaglandin synthesis inhibitors during the organ genetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydroamnios; • the mother and the newborn, at the end of pregnancy, to: - possible prolongation of the bleeding time, and antiplatelet effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor.
Expiration and retention
No special instructions
Interactions with other drugs
The paucity of the data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions were found with the occasional use of ibuprofen. However, it should be noted that Ibuprofen can increase the effects of anticoagulants such as warfarin.
No cases of overdose have been reported.
100 g of gel contain: Active principle: Ibuprofen lysine salt 10 g Excipients: Methyl sodium para-oxybenzoate, ethyl para-oxybenzoate sodium. For the full list of excipients, see section 6.1.
Isopropanol, hydroxyethylcellulose, methyl sodium para-oxybenzoate, ethyl para-hydroxybenzoate sodium, glycerol, lavender essence, purified water.